Catherine Bird
Senior Clinical Trials Manager at King’s College London
Data updated
Research Footprint
Catherine Bird appears in 5 tracked papers (2021–2026), most studied alongside Psilocybin and 5-MeO-DMT, across Safety & Risk Management, Depressive Disorders and Treatment-Resistant Depression (TRD).
Most-cited paper: Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression (1057 citations).
Frequent co-authors: James Rucker, Mathieu Seynaeve and Allan Young.
Background & Research
Catherine Bird works in psychedelic research as part of the Psychoactive Trials Group at the Institute of Psychiatry, Psychology & Neuroscience, King’s College London. She appears on multiple psilocybin and psychedelic clinical trial publications, including studies in depression, headache disorders, and healthy volunteers. Her KCL profile lists her as Senior Clinical Trials Manager based at the Institute of Psychiatry, Psychology & Neuroscience.
Key Impact
She is a key clinical trials researcher in major psychedelic studies, including psilocybin trials for treatment-resistant depression and related neuropsychiatric conditions.
Collaboration Network
30 collaborators· click a node to visit their profile
Full network →Compounds
Topics
Top Collaborators
Affiliations
Institutions, companies, and organisations Catherine Bird is associated with.
King's College London
academicThe Centre for Mental Health Research and Innovation and the Psychoactive Trials Group are actively conducting clinical trials with various psychedelic compounds to develop new care models for treatment-resistant depression, PTSD, and anorexia nervosa.
View stakeholder →COMPASS Pathways
Public BiotechCOMPASS Pathways is a UK-listed biopharmaceutical company developing COMP360 synthetic psilocybin therapy for treatment-resistant depression, with two successful Phase 3 trials making it the leading candidate for the first regulatory approval of a classic psychedelic medicine.
View stakeholder →